Notícias Edgewise Therapeutics Inc - EWTX | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Edgewise Therapeutics Inc (EWTX)
Edgewise Therapeutics Inc (EWTX) Notícias

Edgewise Therapeutics Inc (EWTX)

28,74

-0,92

(-3,10%)

Fechado 28 Dezembro 6:00PM

Atrasado por 15 minutos

28,8399

0,0999

(0,35%)

Após o horário de negociação: 9:59PM

Atrasado por 15 minutos

Capacite seu portfólio: Discussões em tempo real e ideias de negociação acionáveis.

Form 8-K - Current report

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Edgewise Therapeutics

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições